Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Roche’s Perjeta for Breast Cancer Wins Approval

Don't Miss Out —
Follow us on:

(Corrects drug spelling in headline, second paragraph of story published June 8.)

June 8 (Bloomberg) -- Roche Holding AG’s personalized drug treatment for a fast-growing type of breast cancer won approval from U.S. regulators.

Perjeta, chemically known as pertuzumab, is designed to work with the Basel, Switzerland-based company’s Herceptin and chemotherapy to attack breast cancer that has spread in patients who have a certain gene mutation. The Food and Drug Administration today cleared Perjeta for consumer use, Roche’s Genentech unit said in a statement.

To contact the reporter on this story: Anna Edney in Washington at aedney@bloomberg.net.

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.